Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

T. Jeroen N. Hiltermann, MD, discusses findings from phase 1/2 ARTEMIDE-01 trial.

Dr Hiltermann on ARTEMIDE-01 Data With Rilvegostomig in Metastatic NSCLC

Patients with EGFR-mutated NSCLC demonstrated reduced symptom progression when treated with amivantamab plus lazertinib vs osimertinib.

Amivantamab Plus Lazertinib Delays Symptomatic Progression in EGFR+ Advanced NSCLC 

T-DXd showed clinical activity regarding responses and survival outcomes in patients with pretreated HER2-overexpressed metastatic non–small cell lung cancer.

T-DXd Displays Clinical Benefit in HER2-Overexpressed Metastatic NSCLC

Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.

Dr Besse on Results From the CARMEN-LC03 Trial in Nonsquamous NSCLC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

As more therapies emerge for HER2-positive, -low, or -negative breast cancer, pathologists highlight the need for more precise methods of evaluating HER2 expression.

Nuances of HER2 Expression Underscore Need for More Precise Testing in Breast Cancer

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

The phase 2 trial of the gamma-delta T-cell therapy INB-400 plus temozolomide in patients with newly diagnosed GBM has suspended enrollment.

Clinical Development of Gamma-Delta T-Cell Therapy INB-400 Paused in Glioblastoma

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Updated data from a phase 1/2 study showed positive overall survival outcomes with Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer.

Bria-IMT Plus Checkpoint Inhibition Maintains Favorable OS in Metastatic Breast Cancer

Videos

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

Onclive® Publications

September 2014

I often find myself in awe of physicians who travel around the world seeking out the 2 most desirable aspects of medicine-patients in desperate need of medical care and patients with genuinely novel pathology

An International Experience at Home

Based on a current laboratory research project, Zarah Dulce
F. Lucas, MD, discusses microRNAs and their potential to
predict brain metastases in patients with triple-negative and
HER2-positive breast cancer.

From Bedside to Bench

On a recent day in hematology clinic, I stood dutifully by my attending as he sorted through bone marrow slides

Becoming a Champion of Change: Educating Fellows on the Costs of Cancer Care

September 2014

Latest Conference Coverage